NCT00895739Unknown2 期
Alemtuzumab and Low-Dose Cyclosporine-A as Alternative Immunosuppressive Treatment for Severe Aplastic Anemia (SAA) and Single-Lineage Aplastic Patients
Federico II University2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2006年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Safety, as defined by occurrence of adverse effects
研究概览
简要总结
RATIONALE: Immunosuppressive therapies, such as alemtuzumab and cyclosporine, may improve bone marrow function and increase blood cell counts. Giving alemtuzumab together with cyclosporine may be an effective treatment for severe aplastic anemia or acquired marrow failure.
PURPOSE: This phase II trial is studying the side effects of giving alemtuzumab together with cyclosporine and to see how well it works in treating patients with severe aplastic anemia or acquired marrow failure.
详细描述
OBJECTIVES:
Primary
- Determine the safety of alemtuzumab and low-dose cyclosporine, as defined by occurrence of adverse effects, in patients with severe aplastic anemia or single lineage acquired marrow failure.
- Determine the efficacy of this regimen, in terms of overall survival, hematological response (partial and complete response, including time to response) and failure-free survival (failure is defined as no response, chronic treatment-maintained response, or relapse), in these patients.
Secondary
- Evaluate the incidence of adverse effects after treatment.
- Evaluate the long-term safety of alemtuzumab treatment.
- Determine the time to achieve a complete hematological response.
- Determine the proportion of patients maintaining hematological response free of any treatment.
- Determine the incidence of relapse in responding patients.
- Determine the incidence of severe infections.
- Determine the requirement for IV antibiotics and antifungal therapy.
- Determine the requirement for red cell and platelet transfusion.
- Determine the incidence of CMV reactivation.
- Determine the kinetics of immune reconstitution.
- Determine the incidence of paroxysmal nocturnal hemoglobinuria clone (lymphoid or myeloid) development.
- Determine the incidence of clonal evolution (i.e., karyotypic abnormalities or secondary myelodysplasia/leukemia).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Diagnosis of 1 of the following:
- •Severe or very severe aplastic anemia, as defined by the following criteria:
- •Meets ≥ 2 of the following criteria:
- •Absolute neutrophil count < 0.5 x 10^9/L (severe) or < 0.2 x 10^9/L (very severe)
- •Platelet count < 20 x 10^9/L
- •Reticulocyte count < 20 x 10^9/L
- •Hypocellular bone marrow (< 30% cellularity) without evidence of fibrosis or malignant cells
- •Single lineage acquired marrow failure (e.g., pure red cell aplasia, agranulocytosis, amegakaryocytic thrombocytopenia)
- •Paroxysmal nocturnal hemoglobinuria clone allowed
- •Failed first-line therapy with antithymocyte globulin (ATG) and cyclosporine OR not eligible for ATG-based studies
- •Failure is defined as lack of hematological response, requirement for chronic immunosuppressive treatment to sustain response, or relapse
- •Not eligible for a low-risk stem cell transplantation
- •No evidence of risky myelodysplastic syndromes (i.e., IPSS 3-4), as defined by the presence of marrow blast excess or karyotypic abnormalities, or other primitive marrow disease
- •No history of constitutional aplastic anemia (e.g., Fanconi anemia or dyskeratosis congenita)
- •PATIENT CHARACTERISTICS:
- •WHO performance status 0-2
- •Not pregnant or nursing
- •No active malignant tumor within the past 5 years
- •Transaminases ≤ 3 times upper limit of normal (ULN)
- •Albumin ≥ 1.5 g/L
- •Creatinine ≤ 3 times ULN
- •No CMV viremia, as defined by positive PCR or pp65 test
- •No cardiac failure (i.e., ejection fraction < 35%)
- •No other concurrent life-threatening disease (including HIV infection)
- •PRIOR CONCURRENT THERAPY:
- •No prior allogeneic stem cell transplantation
- •At least 2 weeks since prior cyclosporine or filgrastim (G-CSF)
排除标准
- 未提供
结局指标
主要结局
Safety, as defined by occurrence of adverse effects
Overall survival
Hematologic response (partial and complete response, including time to response)
Failure-free survival (failure is defined as no response, chronic treatment-maintained response, or relapse)
次要结局
- Incidence of adverse effects after treatment
- Long-term safety of alemtuzumab treatment
- Time to achieve a complete hematological response
- Proportion of patients maintaining hematological response free of any treatment
- Incidence of relapse in responding patients
- Incidence of severe infections
- Requirement for IV antibiotics and antifungal therapy
- Requirement for red cell and platelet transfusion
- Incidence of CMV reactivation
- Kinetics of immune reconstitution
- Incidence of paroxysmal nocturnal hemoglobinuria (PNH) clone (lymphoid or myeloid) development
- Incidence of clonal evolution (i.e., karyotypic abnormalities or secondary myelodysplasia/leukemia)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic SyndromeMyelodysplastic SyndromesLeukemiaNCT00016419SWOG Cancer Research Network130
已完成
2 期
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic SyndromeMyelodysplastic SyndromesNCT00017550Genzyme, a Sanofi Company
已完成
1 期
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT00634881German CLL Study Group13
进行中（未招募）
不适用
ALEMTUZUMAB AND LOW-DOSE CYCLOSPORINE-A AS ALTERNATIVE IMMUNOSUPPRESSIVE TREATMENT FOR SEVERE APLASTIC ANEMIA (SAA) AND SINGLE-LINEAGE APLASTIC PATIENTS. - AlesaaEUCTR2008-001151-22-ITIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II50
Unknown
1 期
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's LymphomaLymphomaNCT00363090Toronto Sunnybrook Regional Cancer Centre84